Moklar (Moclobemide)

Moclobemide selectively and reversibly inhibits the enzyme monoamine oxidase A (MAO‑A). By blocking MAO‑A, it reduces the breakdown of serotonin, norepinephrine and dopamine, leading to higher concentrations of these neurotransmitters in the brain, which contributes to mood elevation and reduction of depressive signs.

The appropriate dose of Moklar is determined by the prescribing clinician based on the individual’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to therapeutic response and any adverse effects, and patients should follow the prescriber’s specific instructions.

Safety data for moclobemide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers must evaluate each case individually and discuss possible risks with the patient.

To request Moklar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moklar (moclobemide) differs from irreversible MAO inhibitors by offering reversible inhibition of MAO‑A, which results in a lower risk of dietary tyramine interactions. Compared with SSRIs or SNRIs, it may have a faster onset of action for some patients but requires careful monitoring for serotonergic drug interactions.

Moklar should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Moklar is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically advised by a healthcare professional.

The most serious risks include hypertensive crisis, especially when consuming tyramine‑rich foods, and serotonin syndrome when combined with other serotonergic agents. Patients should seek immediate medical attention if they experience severe headache, rapid blood pressure rise, agitation, confusion, or muscle rigidity.

Moklar is contraindicated in patients taking other MAO inhibitors, certain serotonergic drugs (e.g., SSRIs, SNRIs, tramadol), meperidine, or those with severe hepatic impairment. Individuals with a known hypersensitivity to moclobemide or any excipients in the formulation should also avoid its use.